MedDataX Logo

Characterization of Breg Cells

NCT ID: NCT02615951

Last Updated: 2021-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-02

Study Completion Date

2018-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recently, it has been shown that B cells could also have regulatory functions through the secretion of interleukin 10 (IL-10). They are called the B regulatory cells (Breg). In the mouse model the most commonly used of rheumatoid arthritis, collagen-induced arthritis (CIA), the transfer Breg helps prevent the development of CIA and cure established arthritis. The investigators have recently shown that Breg were decreased in patients with RA compared to controls and that the rate of Breg was inversely correlated with disease activity and autoantibody. These results thus suggest that the lack of IL-10 secretion by B cells plays an important role in the pathophysiology of RA. Nevertheless, in humans, the Breg remain poorly understood. The main objective of this project is to better characterize the B capable of producing IL-10 both in subjects with RA and controls. Understanding which induces the secretion of IL-10 by B could allow to consider new therapeutic approaches in autoimmune diseases, including in RA.

The investigators therefore aim to identify nutrient transporters, chemokine receptors, genes and surface proteins differentially expressed between Breg and other B cells in patients with RA and in controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rational: Rheumatoid arthritis (RA), the most common inflammatory joint disease, is often associated with irreversible joint destruction and can involve the prognosis of patients. If treatments to stabilize the disease are now available, research continues to try to permanently cure the disease. It is well established that the B cells have a pathogenic role in RA. More recently, it has been shown that B cells could also have regulatory functions through the secretion of interleukin 10 (IL-10). They are called the B regulatory cells (Breg). In the mouse model the most commonly used of rheumatoid arthritis, collagen-induced arthritis (CIA), the transfer Breg helps prevent the development of CIA and cure established arthritis. The investigators have recently shown that Breg were decreased in patients with RA compared to controls and that the rate of Breg was inversely correlated with disease activity and autoantibody levels. These results thus suggest that the lack of IL-10 secretion by B cells plays an important role in the pathophysiology of RA. Nevertheless, in humans, the Breg remain poorly understood. The project's main objective is to better characterize the B capable of producing IL-10 both in subjects with RA and controls. Understanding which induces the secretion of IL-10 by B could allow to consider new therapeutic approaches in autoimmune diseases, including in RA.

Objectives:

Principal: To identify nutrient transporters and chemokine receptors differentially expressed between Breg and other B cells in patients with RA.

Secondary:

* To identify genes and surface proteins differentially expressed between Breg and other B Lymphocytes (BL) in patients with RA.
* To identify nutrient transporters, chemokine receptors, genes and surface proteins differentially expressed between Breg and other BL in healthy subjects.
* To compare the expression of nutrient transporters, chemokine receptors, genes and surface proteins between Breg Breg controls and subjects with RA.

Methods:

Design: Cross-sectional study involving bicentric rheumatology services in Montpellier and Nîmes to recruitment; our research team at the Translational IGMM Nîmes and immunology laboratory for biological analyzes.

Population:

* RA: patient meets the criteria ACR (American College of Rheumatology) -EULAR (European League Against Rheumatism) 2010, naïve and biotherapy with corticosteroids less than 10 mg / day, stable for at least a week.
* Controls: matched for age and sex to RA patients, with no systemic disease.

Endpoints

* Main: the average flow cytometry fluorescence intensity nutrient carriers and the percentage of BL expressing the different chemokine receptors
* Secondary: transcriptome analysis and proteomics surface with cytometric confirmation of protein expression of RNA and proteins identified.

Number of subjects: 50 controls and 50 RA patients (10 each for each of the 3 methods of comparison Breg / B IL10- and 10 each for each of the two stages of validation). Each patient will have a visit. The expected study duration is 2 years.

Statistical analysis: Comparing ratios B + IL-10 / IL-10-B between RA patients and controls by Student or Mann-Whitney tests.

Expected Results and Prospects: This project will allow us to better define and understand the Breg in patients with RA and in controls. If the investigators can find specific extracellular markers for Breg, this will simplify the further study of these cells. Understanding allowing BL becoming regulator and this explains the lack of IL-10 by the BL in RA could open new therapeutic perspectives.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers Arthritis, Rheumatoid

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Regulatory B cells (Breg) Genes Cell surface proteins Nutrient transporters Chemokine receptors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nutrient transporters study

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression

Group Type OTHER

blood sampling

Intervention Type OTHER

Blood sample retrieval for biological and genetic analysis and comparison

Chemokine receptors study

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression

Group Type OTHER

blood sampling

Intervention Type OTHER

Blood sample retrieval for biological and genetic analysis and comparison

Genes study

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression

Group Type OTHER

blood sampling

Intervention Type OTHER

Blood sample retrieval for biological and genetic analysis and comparison

Protein surface study

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression

Group Type OTHER

blood sampling

Intervention Type OTHER

Blood sample retrieval for biological and genetic analysis and comparison

Protein surface & genes data validation

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from "protein surface study" and "genes study" arms analysis.

Group Type OTHER

blood sampling

Intervention Type OTHER

Blood sample retrieval for biological and genetic analysis and comparison

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sampling

Blood sample retrieval for biological and genetic analysis and comparison

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* RA responding to ACR/EULAR 2010 criteria

Exclusion Criteria

* steroid\> 10 mg/d
* previous use of biological disease-modifying antirheumatic drug (DMARD)
* age\<18 years
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nīmes

OTHER

Sponsor Role collaborator

Institut de Génétique Moléculaire de Montpellier

OTHER

Sponsor Role collaborator

University Hospital, Montpellier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Claire I Daien, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Montpellier teaching hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Regional University Hospital

Montpellier, Hérault, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9461

Identifier Type: -

Identifier Source: org_study_id